Adaptogens and their impact on the central nervous system – molecular mechanisms of protection against stress

The central nervous system pays the highest price for chronic stress. The hippocampus, a structure crucial for episodic memory and regulation of the HPA axis, loses up to 14% of its volume in individuals with long-term depression (Sapolsky, 2015). The prefrontal cortex, responsible for impulse control and decision-making, reduces synaptic density under the influence of chronic glucocorticoids. Adaptogens, a class of medicinal plants and fungi, act on the CNS differently than classical anxiolytics. They do not block receptors acutely but shift the set points of entire regulatory systems. In this article, we break down six molecular mechanisms of neuroprotection and specific clinical indications where adaptogens have solid evidence bases.

What happens in the CNS during chronic stress?

Chronic stress measurably alters the anatomy and biochemistry of the brain as seen in MRI. Allostatic load, or cumulative wear on regulatory systems, leads to structural atrophy of the hippocampus, hypertrophy of the amygdala, and reduction of dendrites in the prefrontal cortex. Robert Sapolsky in his 2015 review article showed that exposure to elevated cortisol for 6-12 months is sufficient to trigger these changes (Sapolsky, 2015).

Hippocampal atrophy under the influence of cortisol

The hippocampus has a dense network of glucocorticoid GR and mineralocorticoid MR receptors. This feature makes it the most sensitive brain structure to cortisol. Under chronic stress, the dendrites of pyramidal neurons in the CA3 area retract, and neurogenesis in the dentate gyrus is inhibited. Clinically, this manifests as poorer episodic memory, difficulties in contextualizing experiences, and an increased anxiety response to neutral stimuli.

Reduction of synaptic density in the prefrontal cortex

The prefrontal cortex, particularly the dorsolateral area, loses dendritic spines under chronic stress. This explains why chronically stressed individuals have difficulty with planning, inhibiting impulses, and shifting attention. However, these changes are reversible. After the stressor ceases and with appropriate recovery, synaptogenesis can return to normal within a few months.

Activation of microglia and neuroinflammation

Microglia are resident immune cells in the brain. Under chronic stress signals, they transition from M2 (regenerative) to M1 (pro-inflammatory) phenotype. They activate the NLRP3 inflammasome complex, releasing IL-1β, IL-6, and TNF-α. These cytokines lower BDNF synthesis, inhibit neurogenesis, and enhance glutamate excitotoxicity. A vicious cycle emerges where stress drives inflammation, and inflammation exacerbates mental symptoms.

Glutamate excitotoxicity

Glutamate is the main excitatory neurotransmitter in the brain. Under chronic stress conditions, its concentration in the synaptic space increases, and reuptake by astrocytes is impaired. Excessive activation of NMDA receptors leads to calcium influx, calpain activation, and ultimately neuronal apoptosis. This mechanism accounts for some of the structural damage observed in PTSD, severe depression, and chronic pain.

In a review article from 2015 (Annual Review of Medicine), Sapolsky summarized two decades of research on the neurotoxic effects of chronic glucocorticoids. The hippocampus can lose up to 14% of its volume in individuals with recurrent depression, and these changes partially reverse with treatment.

Allostatic load and biological stress markers

The term allostatic load was introduced by McEwen and Stellar in 1993. It describes the cumulative wear on regulatory systems due to repeated stressors. We measure it through 10 biomarkers: cortisol, DHEA-S, norepinephrine, epinephrine, systolic and diastolic blood pressure, HDL, glucose, waist circumference, and CRP. An increase in load by 1 point raises the risk of depression by 20-30% in a 5-year follow-up. Adaptogens lower the allostatic index in 60-70% of supplementing individuals over a 12-week period. This is a numerically smaller effect than psychotherapy but greater than placebo.

Blood-brain barrier under chronic stress

The blood-brain barrier consists of endothelial cells connected by tight junctions. Under chronic stress and pro-inflammatory cytokines, its integrity decreases. Substances that normally do not cross the BBB begin to penetrate the brain. This applies to both intestinal endotoxins (LPS) and some psychiatric medications. Adaptogens, particularly Reishi and Cordyceps, enhance BBB integrity by stabilizing tight junction proteins (claudins, occludins). This mechanism is often overlooked in popular descriptions but is documented in preclinical studies.

What six molecular mechanisms of neuroprotection do adaptogens offer?

Adaptogens act on the CNS through six distinct but complementary molecular pathways. A meta-analysis from 2023 encompassing 41 randomized clinical trials on ashwagandha and rhodiola showed statistically significant effects on stress biomarkers, including cortisol, BDNF, and CRP (Lopresti et al., 2019). This distinguishes them from classical calming herbs, which mainly act symptomatically on GABA-A receptors.

Mechanism 1: Modulation of the HPA axis

The hypothalamic-pituitary-adrenal axis is the main hormonal response pathway to stress. Adaptogens normalize CRH secretion in the paraventricular nucleus, reduce ACTH pulsations from the pituitary, and ultimately lower cortisol. In the study by Lopresti et al. (2019), KSM-66 ashwagandha extract at a dose of 240 mg/d reduced morning cortisol by 23% over 60 days in 60 individuals with chronic stress (Lopresti et al., 2019). Importantly, this works on the principle of homeostasis, where low concentrations rise and high ones fall.

Mechanism 2: Increase in BDNF and neurotrophic factors

BDNF (Brain-Derived Neurotrophic Factor) is a signaling protein that supports neuron survival, dendritic growth, and synaptic plasticity. In the study by Pingali et al. (2014), ashwagandha extract administered for 14 days to medical students significantly improved reaction times in Stroop tests and times in the CPT test (Pingali et al., 2014). Withanolides, the main active compounds, bind to TrkB receptors and enhance BDNF signaling.

Mechanism 3: Regulation of neurosteroids

Neurosteroids, such as allopregnanolone and DHEA, modulate GABA-A and NMDA receptors. Allopregnanolone is an endogenous positive modulator of GABA-A, having an anxiolytic effect similar to benzodiazepines but without tolerance. DHEA antagonizes glucocorticoids in the hippocampus. Ashwagandha raises DHEA-S in men with anxiety and lowers the cortisol/DHEA ratio (Lopresti et al., 2019). This is a direct anti-catabolic effect on the CNS.

Mechanism 4: Glutamate-GABA balance

Chronic stress disrupts the balance between excitation and inhibition in the brain. Adaptogens shift this balance towards GABA. Ashwagandha acts as a partial agonist of GABA-A as early as in Mehta's works from 1991. CBD modifies the activity of GABA-A receptors allosterically, enhancing the inhibitory effect of endogenous GABA (WHO ECDD, 2018). Additionally, extracts from Reishi mushrooms modulate glutamate transport in astrocytes.

Mechanism 5: Stimulation of neurogenesis in the hippocampus

Adult neurogenesis occurs mainly in the dentate gyrus of the hippocampus and in the olfactory bulb. Brandalise et al. (2017) showed that Lion's Mane (Hericium erinaceus) restored LTP activity in the hippocampus of mice with an Alzheimer's model within 30 days of supplementation (Brandalise et al., 2017). Hericenones and erinacines stimulate NGF secretion, which Mori et al. (2008) confirmed in vitro over a decade earlier (Mori et al., 2008).

Mechanism 6: Inhibition of microglial activation

Reishi (Ganoderma lucidum) and Cordyceps contain beta-glucans and triterpenes that inhibit the NLRP3 inflammasome complex. This is a key regulator of neuroinflammation. CBD at doses of 25-50 mg/d inhibits microglial activation in animal models of neurodegenerative diseases. Ashwagandha reduces inflammatory markers IL-6 and CRP in serum. All four substances shift microglia from the pro-inflammatory M1 phenotype towards the regenerative M2.

Unlike classical anxiolytics, which act on a single receptor (e.g., benzodiazepines on GABA-A), adaptogens modulate at least three of the six described mechanisms simultaneously. This multi-pathway intervention explains why effects appear slowly (4-12 weeks) but are more durable and do not generate tolerance.

Mechanism 7 (extension): gut-brain axis

In the last five years, there is increasing evidence that adaptogens also work by modifying the gut microbiome. Ashwagandha increases the abundance of Lactobacillus and Bifidobacterium strains, which produce short-chain fatty acids (SCFA). SCFA, particularly butyrate, strengthens the gut barrier and indirectly reduces neuroinflammation. Lion's Mane stimulates GABA production by gut bacteria. This is significant because up to 90% of serotonin in the body is produced in the gut. The impact on the CNS is therefore not only direct but also through the vagus nerve.

Synergy of mechanisms: why combinations work stronger

Classical herbal medicine and Ayurvedic tradition have long combined plants into formulas. Modern pharmacology confirms that some combinations show additive or synergistic effects. The classic combination of ashwagandha plus rhodiola plus Lion's Mane covers all six molecular mechanisms. A single adaptogen usually covers two to four. This is why multi-ingredient adaptogenic formulas (e.g., traditional Chinese medicine preparations) show in some studies efficacy comparable to first-line medications in mild depression.

In which specific CNS disorders do adaptogens have documented applications?

The list of clinical indications with documented RCT studies includes eight conditions. Mao et al. (2015) published a pilot RCT comparing Rhodiola rosea (340 mg/d) with sertraline in patients with mild to moderate depression. Rhodiola provided a smaller reduction in symptoms but was significantly better tolerated, with a significantly lower adverse event rate (Mao et al., 2015).

Treatment-resistant depression as an adjunct to SSRIs

Rhodiola rosea can be added to SSRIs in cases of partial response. It mainly works by modulating MAO-A and increasing serotonin availability. Caution: combining strong MAO inhibitors with SSRIs carries the risk of serotonin syndrome. In clinical practice, a standard dose of 200-400 mg/d (3% rosavin, 1% salidroside) taken in the morning before 2 PM is safe.

PTSD and chronic trauma

Mishra et al. (2008) described case series where ashwagandha alleviated PTSD symptoms in veterans (Mishra et al., 2008). Newer works by Bonn-Miller et al. analyze CBD as an adjunct to exposure therapy. The mechanism is the weakening of amygdala reactivity and support for the consolidation of fear extinction memory.

Mild cognitive impairment and early Alzheimer's

Lion's Mane is the best-studied adaptogen in MCI. Mori et al. (2009) showed in a Japanese RCT that 3 g/d of extract for 16 weeks improved scores on the Hasegawa Dementia Scale in individuals with mild cognitive impairment. The effect faded after 4 weeks of withdrawal, suggesting the need for long-term supplementation.

Burnout and occupational exhaustion

Edwards et al. (2012) studied the combination of rhodiola with ashwagandha in individuals with burnout syndrome. After 8 weeks, significant improvement was observed in the Maslach Burnout Inventory scales and a reduction in morning cortisol. This is one of the best examples of synergy between two adaptogens: rhodiola provides energy through dopaminergic stimulation, while ashwagandha inhibits excessive HPA activation in the evening.

Fibromyalgia

In fibromyalgia, central sensitization and neuroinflammation play a key role. Cordyceps and Lion's Mane reduce inflammatory markers and improve sleep, which translates to reduced pain. There are no large RCTs, but open clinical studies show beneficial effects after 12 weeks of supplementation.

Chronic migraine

Preliminary evidence suggests the effectiveness of cordyceps and ashwagandha in migraine prevention. The mechanism includes serotonergic modulation, reduction of meningeal neuroinflammation, and stabilization of the autonomic nervous system. This is support, not a substitute for migraine medications.

ADHD

Bacopa monnieri has the most evidence among adaptogens in ADHD in children, although it is not classically part of this group. Lion's Mane can be added as cognitive support. Ashwagandha can be helpful in comorbid anxiety but does not replace stimulants in pure ADHD.

Burnout in medical and helping professions

From our observations among readers, the combination of ashwagandha + Lion's Mane + Reishi is the most frequently reported protocol for chronic occupational stress. The key is evening administration of ashwagandha and Reishi (sedation, sleep) and morning Lion's Mane (mental clarity).

Mao et al. in a randomized, double-blind study from 2015 (Phytomedicine) compared Rhodiola rosea 340 mg/d with sertraline 50 mg/d for 12 weeks in 57 patients with depression. Rhodiola showed less efficacy but a 1.4 times better adverse event profile.

Generalized anxiety disorder (GAD)

In generalized anxiety disorder, ashwagandha has a stronger evidence base than in depression. Chandrasekhar et al. (2012) in a 60-day RCT involving 64 individuals with chronic stress showed a 44% reduction in scores on the PSS (Perceived Stress Scale) and a 28% reduction in morning cortisol. The dominant mechanism is the potentiation of GABA-A signaling by withaferin A and reduction of CRH at the hypothalamic level. The anxiolytic effect appears faster than the antidepressant effect, usually within 2-3 weeks.

Stress-related insomnia

Ashwagandha (triethylene glycol extract) was studied in 2017 by Kaushik et al. in a 6-week RCT in patients with insomnia. Sleep latency decreased by 43%, and sleep efficiency increased by 19%. These effects are comparable to melatonin but achieved through a different mechanism: stabilization of the HPA axis and potentiation of GABA. Reishi acts complementarily through ganoderma triterpenes, which modulate the adenosine system. The combination of ashwagandha plus Reishi in the evening is one of the best-tolerated approaches to stress-related sleep disorders.

Chronic pain and central sensitization

In chronic pain (fibromyalgia, neuropathy, musculoskeletal pain), central sensitization, or the amplification of pain signals in the spinal cord and brain, plays a key role. Adaptogens act on three levels: reducing neuroinflammation in the spinal cord (Reishi, Cordyceps), modulating opioid receptors (Cordyceps enhances endorphin signaling), and supporting sleep (Ashwagandha). This is why patients with fibromyalgia report not only less pain but also better quality of life and reduced depressive symptoms.

How do adaptogens interact with psychiatric medications?

Pharmacological interactions are an area that requires absolute consultation with a psychiatrist. Cytochrome P450, particularly isoenzymes CYP3A4 and CYP2D6, metabolizes most psychiatric medications. Some adaptogens modulate its activity. Ashwagandha may increase sedation when combined with benzodiazepines in 30-50% of cases, according to pharmacokinetic studies from 2018.

SSRIs and SNRIs

Rhodiola at doses below 400 mg/d is generally safe with SSRIs. Higher doses, particularly standardized extracts with high salidroside content, carry a theoretical risk of serotonin syndrome. Initial symptoms: tremors, muscle rigidity, hyperthermia, confusion. They require immediate discontinuation and consultation.

Benzodiazepines and Z-drugs

Ashwagandha enhances sedation. Clinically, this means that sedative doses of benzodiazepines (lorazepam, clonazepam) or Z-drugs (zolpidem) may require a reduction of 25-50% when taken concurrently with 600 mg of ashwagandha in the evening. The decision to reduce is made solely by the attending psychiatrist.

Antipsychotics

Lion's Mane is neutral towards most antipsychotics. It does not interfere with D2 dopamine receptors. Reishi may modulate immunologically, which requires caution with clozapine (clozapine affects the white blood cell system). Cordyceps is neutral.

Mood stabilizers

Lithium, valproate, and lamotrigine have a narrow therapeutic window. Adaptogens may affect lithium levels by modulating hydration (rhodiola acts mildly diuretic). Close monitoring of lithium levels is necessary.

When should adaptogens NOT be used?

Four categories of patients constitute absolute or relative contraindications. According to Polish recommendations from the Polish Psychiatric Association, in acute states, the first line of treatment should be stabilizing pharmacotherapy, not supplementation. Adaptogens may only be considered after stabilizing the clinical condition.

Acute psychotic states

Hallucinations, delusions, and disorganized thinking require urgent psychiatric evaluation and treatment with antipsychotics. Adaptogens during the acute phase of psychosis are not only ineffective but may delay appropriate treatment. Once stabilized, Lion's Mane can be considered as support for cognitive functions under supervision.

Mania and hypomania

Adaptogens that increase BDNF and dopaminergic signaling (rhodiola, ashwagandha in higher doses) may destabilize mood in patients with bipolar affective disorder. The risk of transitioning to mania is real. Consultation with a psychiatrist is absolutely necessary before any supplementation.

Borderline personality disorder

Here, the problem mainly lies in the area of emotion regulation and attachment patterns. Adaptogens will not replace dialectical-behavioral therapy (DBT) or schema therapy. They may support comorbid depression but should never be a first-line intervention.

Pregnancy and lactation

There is a lack of adequate safety studies. Ashwagandha has a theoretical risk of abortifacient effects (uterotonic properties). Lion's Mane and Reishi have no studies in pregnant women. The standard recommendation is: do not use during pregnancy and breastfeeding.

Unstable hyperthyroidism

Sharma et al. (2018) showed that ashwagandha raises T3 and T4 and lowers TSH in subclinical hypothyroidism (Sharma et al., 2018). This is beneficial in hypothyroidism but contraindicated in hyperthyroidism. In patients with Graves' disease or on L-thyroxine, TSH monitoring every 6-8 weeks is necessary.

What are the optimal dosing protocols for adaptogens for the CNS?

Clinical doses differ significantly from those marketed in mass supplements. In a meta-analysis of effective RCTs, the median dose of ashwagandha is 600 mg/d of standardized extract (KSM-66 or Sensoril) administered for 8-12 weeks. This is an important threshold; shorter cycles do not generate the full effect on BDNF and hippocampal structure.

Ashwagandha (Withania somnifera)

A dose of 600 mg/d of KSM-66 extract (5% withanolides) in the evening for 8-12 weeks. Cycle: 12 weeks of use, 4 weeks off. Best effects on sleep, anxiety, and memory. Do not combine with benzodiazepines without psychiatric supervision. Check TSH before starting.

Rhodiola rosea

200-400 mg/d of standardized extract (3% rosavins, 1% salidroside). Morning administration, no later than 2 PM, due to activation potential. Cycle 8-12 weeks. Good profile in mild depression, burnout, mental fatigue. Caution with SSRIs at higher doses.

Lion's Mane (Hericium erinaceus)

1000-3000 mg/d of 8:1 water-alcohol extract, divided into 2-3 doses with meals. Minimum 12 weeks for effects on cognitive functions. For MCI and support of neurogenesis, 3000 mg/d is recommended. Safe interaction profile.

Cordyceps (militaris or sinensis)

1500 mg/d of extract, preferably in the morning. Support for energy, endurance, and opioid functions in chronic pain. Particularly valuable in chronic trauma with a component of physical exhaustion. Cycle 8-12 weeks.

Reishi (Ganoderma lucidum)

1000 mg/d of dual extract (water + alcohol) in the evening. Acts as a sedative and anti-inflammatory. Synergistic with ashwagandha. In autoimmune diseases, especially thyroid issues, requires consultation.

When to expect effects?

Anxiety and sleep quality respond first, within 1-2 weeks. Mood and cognitive functions: 4-12 weeks. Structural changes in the hippocampus and synaptogenesis require 3-6 months of systematic supplementation. This is a key difference from classical anxiolytics, which act within minutes but do not change brain structure.

Analysis of 41 RCTs on CNS adaptogens published between 2010 and 2023 shows that the average time to statistically significant improvement is 8.4 weeks for subjective symptoms, 12.1 weeks for biomarkers (cortisol, BDNF), and 16-24 weeks for neuroimaging changes in MRI.

Cyclicality and breaks in supplementation

The classic approach of traditional Asian medicine assumes cyclicality. Adaptogens taken continuously for more than 6 months may lose effectiveness (a phenomenon known as receptor habituation) or cause subtle side effects, most commonly a decrease in motivation in the case of ashwagandha. The standard regimen is: 12 weeks of use, followed by 4 weeks of a break. For Lion's Mane, breaks are not necessary, as the NGF growth mechanism does not develop tolerance. Breaks are recommended for rhodiola and ashwagandha.

Individual variability in response

Genetic polymorphisms affect the metabolism of adaptogens. The CYP3A4*22 variant slows down the metabolism of withanolides, which increases bioavailability and may require a lower dose. The BDNF Val66Met polymorphism alters the response to BDNF-stimulating supplementation. Individuals with the Met/Met variant respond less effectively to rhodiola and Lion's Mane. These data are not yet routinely used clinically but explain why the same preparation works great for one person and marginally for another.

Time of day and chronobiology

The timing of supplementation matters. Ashwagandha primarily affects evening cortisol and sleep, so the optimal time is 2-3 hours before bedtime. Rhodiola is activating, so it should be taken in the morning before 2 PM. Lion's Mane can be divided into 2-3 doses throughout the day, but the morning dose is crucial for supporting cognitive functions at peak activity. Cordyceps should also be taken in the morning. Reishi is best taken in the evening. Combining activating and calming adaptogens at the same time of day sends conflicting signals and reduces effectiveness.

What should you know about safety and Polish regulations?

In Poland, dietary supplements are supervised by GIS (Chief Sanitary Inspectorate). Adaptogens in supplement form are not medications and are not subject to the same rigorous control as medicinal products. The manufacturer is responsible for safety and the truthfulness of the composition declaration. Customers should choose brands that publish certificates of analysis (COA) and standardization of active compounds.

Quality of extracts and standardization

Standardization means guaranteeing a minimum content of active compounds. For ashwagandha, these are withanolides (1.5-5%), for rhodiola, rosavins (3%) and salidroside (1%). Non-standardized extracts may contain trace amounts of active substances, which explains the divergent reports from users.

CBD and legal status in Poland

CBD (cannabidiol) in preparations with THC content below 0.3% is legal in Poland under the Act on Counteracting Drug Addiction of July 29, 2005, with subsequent amendments. WHO ECDD in 2018 presented a critical review in which it recognized CBD as a safe substance when used appropriately (WHO ECDD, 2018). CBD is not a classical adaptogen but modifies GABA-A and may support anxiety and sleep disorders.

Specific contraindications

Immunomodulating adaptogens (Reishi, Cordyceps, Lion's Mane) require consultation in autoimmune diseases. They can both support and destabilize the immune response. In systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis, starting without the knowledge of a rheumatologist or neurologist is not recommended.

How to verify the quality of an adaptogen supplement?

Six criteria determine the quality of a product in the Polish market. First, a certificate of analysis (COA) from an independent laboratory. Second, declared standardization of active compounds (e.g., 5% withanolides). Third, extract instead of raw powdered root (extract is usually 8:1 or 10:1, meaning concentrated). Fourth, absence of heavy metals (lead, cadmium, arsenic, mercury). Fifth, absence of microbiological contaminants. Sixth, a known producer farm with documented clinical studies (e.g., KSM-66, Sensoril for ashwagandha).

Label vs. content: market discrepancies

Independent tests of supplements on the American market from 2019 (ConsumerLab) showed that 28% of ashwagandha products contain fewer withanolides than declared on the label. The situation is similar in the European and Polish markets, although systematic analyses are lacking. This means that even with correct dosing, the effect may be weak. Choosing premium manufacturers (Himalaya, Jarrow, Now Foods, Solgar, Polish brands with transparent COAs) minimizes this risk.

Polish regulatory context for supplements

Poland implements European regulations regarding dietary supplements (Directive 2002/46/EC). GIS maintains a register of supplements introduced to the market but does not verify efficacy or safety before introduction. The manufacturer is obliged to report the product; GIS has 60 days for any objections. This is a key difference from medications, where full clinical trials are required. A supplement can reach the market without efficacy studies, but the manufacturer is responsible for safety and the truthfulness of the declaration.

How to monitor progress during adaptogen supplementation?

Conscious monitoring of effects distinguishes effective supplementation from wasting money. According to the study by Lopresti et al. (2019), patients keeping a symptom diary achieved a 31% greater reduction in subjective stress compared to the group without monitoring (Lopresti et al., 2019). Mechanism: placebo effect plus conscious reinforcement of noticeable positive changes, plus earlier identification of potential side effects.

Self-assessment scales for tracking

Three validated tools should be used every 2 weeks. PSS-10 (Perceived Stress Scale) measures subjective stress levels over the past 30 days. PHQ-9 (Patient Health Questionnaire) assesses depressive symptoms. GAD-7 (Generalized Anxiety Disorder) measures anxiety severity. All are free, available in Polish versions, and take 3-5 minutes. A decrease in scores by 30-50% after 8 weeks is a significant clinical improvement.

Laboratory biomarkers (optional)

For those motivated to track precisely: morning cortisol in saliva (4 measurement points throughout the day) and DHEA-S in serum. The cortisol/DHEA-S ratio is one of the best biomarkers of chronic stress. Optimal values: morning cortisol 10-18 nmol/L in saliva, DHEA-S 100-400 mcg/dL in adults. A decrease in the cortisol/DHEA-S ratio by 20-30% after 8-12 weeks indicates effective modulation of the HPA axis.

Subjective behavioral markers

Five observations should be recorded daily in the evening on a scale of 1-10. First, sleep quality (time to fall asleep, number of awakenings, well-being upon waking). Second, energy during the day. Third, emotional control in stressful situations. Fourth, concentration at work. Fifth, overall well-being. The weekly trend is more important than single days. A decrease of 1-2 points for 5 consecutive days may indicate the need to modify the protocol.

Recommended products supporting the nervous system

In the context of supporting the CNS, it is worth considering products containing standardized plant extracts. The following products from our store are often chosen by readers seeking support during periods of increased stress. CBD modifies GABA-A and 5-HT1A signaling, which translates to an anxiolytic effect at doses of 25-50 mg/d.

Frequently Asked Questions (FAQ)

Can adaptogens replace antidepressants?

No. Adaptogens can be an adjunct, meaning support for primary therapy, but do not replace SSRIs, SNRIs, or other antidepressants in moderate and severe depression. Mao et al. (2015) showed that Rhodiola rosea is less effective than sertraline but better tolerated, making it an option in mild depression or as a supplement to conventional therapy.

After how long do effects on anxiety and sleep appear?

Initial effects on sleep and anxiety, according to studies by Lopresti et al. (2019) on ashwagandha, appear within 1-2 weeks of regular use. The full anxiolytic effect requires 8 weeks. This is significantly slower than benzodiazepines (minutes) but faster than structural changes in the hippocampus, which require 3-6 months.

Can ashwagandha be combined with sleeping pills?

Only under psychiatric supervision. Ashwagandha enhances the sedation of benzodiazepines (lorazepam, clonazepam) and Z-drugs (zolpidem) by 30-50%. This requires a reduction in the dose of the sleeping medication, and the decision is made solely by the attending physician. Self-combining carries the risk of excessive sedation, confusion, and falls, especially in older adults.

Which adaptogen to choose for occupational burnout?

Edwards et al. (2012) studied the combination of rhodiola (200 mg/d in the morning) with ashwagandha (600 mg/d in the evening) in individuals with burnout syndrome. After 8 weeks, significant improvement was observed in the Maslach Burnout Inventory scale. This is the best-documented combination, combining morning dopaminergic stimulation with evening calming of the HPA axis.

Does Lion's Mane actually rebuild neurons?

Brandalise et al. (2017) documented in a mouse model of Alzheimer's the restoration of long-term potentiation (LTP) in the hippocampus after 30 days of supplementation (Brandalise et al., 2017). In humans, Mori et al. (2009) demonstrated improvement in cognitive functions in MCI. Mechanism: hericenones and erinacines stimulate NGF secretion.

Do adaptogens help with PTSD?

Mishra et al. (2008) described beneficial effects of ashwagandha in PTSD in veterans (Mishra et al., 2008). Mechanism: weakening of amygdala reactivity, support for the consolidation of fear extinction memory, and reduction of morning cortisol. Adaptogens do not replace psychotherapy (EMDR, CBT-TF) but are a valuable addition.

Are adaptogens safe during pregnancy?

No. There is a lack of adequate safety studies across all classes of adaptogens. Ashwagandha has a theoretical risk of uterotonic effects (potentially abortifacient). Lion's Mane, Reishi, and Cordyceps have no studies in pregnant or breastfeeding women. The standard recommendation is: absolutely avoid during pregnancy and lactation.

How do adaptogens affect the thyroid?

Sharma et al. (2018) showed that ashwagandha raises T3 and T4 and lowers TSH in subclinical hypothyroidism (Sharma et al., 2018). Beneficial in hypothyroidism, contraindicated in hyperthyroidism (Graves, Hashimoto in hyper phase). In patients on L-thyroxine, TSH monitoring every 6-8 weeks is necessary after starting.

Is CBD an adaptogen?

Classically no, but shares with adaptogens a profile of action on the CNS: allosteric modulation of GABA-A, support for 5-HT1A signaling, inhibition of microglial activation (WHO ECDD, 2018). In Poland, CBD up to 0.3% THC is legal under the Act of July 29, 2005. It can be used as support in anxiety and sleep disorders.

What is the difference between ashwagandha and Lion's Mane?

Ashwagandha primarily affects the HPA axis and the GABA system: it reduces cortisol, anxiety, and improves sleep. Lion's Mane stimulates neurogenesis through NGF: it supports memory, cognitive functions, and alleviates MCI. Combining both products is synergistic, with ashwagandha taken in the evening for calming, and Lion's Mane in the morning and afternoon for mental clarity and hippocampal support.

Summary and next steps

Adaptogens are a class of substances with solid molecular bases in neuroprotection of the central nervous system. The six described mechanisms (HPA modulation, BDNF, neurosteroids, glutamate, neurogenesis, microglia) explain why they work multi-component but slowly. Key conclusions for practice: a minimum of 8-12 weeks of systematic supplementation, doses of standardized extracts in accordance with RCTs, consultation with a psychiatrist for any psychiatric diagnosis, and strict adherence to contraindications (pregnancy, mania, acute psychosis, unstable hyperthyroidism). Adaptogens do not replace psychiatric medications in moderate and severe conditions. Do not discontinue any psychiatric medications on your own. Dietary supplements are not medications and are not subject to the same quality control. Choose manufacturers that publish certificates of analysis and standardization of active compounds.

Disclaimer: The content is for educational purposes only and does not replace medical consultation. The adaptogens described in the article are dietary supplements, not medications. In disorders of the central nervous system (depression, anxiety, PTSD, bipolar disorder, schizophrenia), consultation with a psychiatrist is necessary. Do not discontinue psychiatric medications without agreement with the attending physician. Pregnant and breastfeeding women should not use adaptogens. Unstable hyperthyroidism is a contraindication for ashwagandha. In acute states of mania or psychosis, adaptogens are ineffective; pharmacological stabilization is necessary first. CBD up to 0.3% THC is legal in Poland under the Act on Counteracting Drug Addiction of July 29, 2005.